HUE047918T2 - PHD inhibitor hatású kondenzált biciklusos heteroarilszármazékok - Google Patents

PHD inhibitor hatású kondenzált biciklusos heteroarilszármazékok

Info

Publication number
HUE047918T2
HUE047918T2 HUE16715122A HUE16715122A HUE047918T2 HU E047918 T2 HUE047918 T2 HU E047918T2 HU E16715122 A HUE16715122 A HU E16715122A HU E16715122 A HUE16715122 A HU E16715122A HU E047918 T2 HUE047918 T2 HU E047918T2
Authority
HU
Hungary
Prior art keywords
activity
bicyclic heteroaryl
fused bicyclic
heteroaryl derivatives
phd inhibitors
Prior art date
Application number
HUE16715122A
Other languages
English (en)
Hungarian (hu)
Inventor
Saleh Ahmed
Gregory Barker
Hannah Canning
Richard Davenport
David Harrison
Kerry Jenkins
David Livermore
Susanne Wright
Natasha Kinsella
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of HUE047918T2 publication Critical patent/HUE047918T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE16715122A 2015-03-18 2016-03-17 PHD inhibitor hatású kondenzált biciklusos heteroarilszármazékok HUE047918T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds

Publications (1)

Publication Number Publication Date
HUE047918T2 true HUE047918T2 (hu) 2020-05-28

Family

ID=53051992

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16715122A HUE047918T2 (hu) 2015-03-18 2016-03-17 PHD inhibitor hatású kondenzált biciklusos heteroarilszármazékok

Country Status (31)

Country Link
US (1) US10287286B2 (enExample)
EP (1) EP3271357B1 (enExample)
JP (1) JP6726681B2 (enExample)
KR (1) KR102609431B1 (enExample)
CN (1) CN107531698B (enExample)
AU (1) AU2016234209B2 (enExample)
BR (1) BR112017019653B1 (enExample)
CA (1) CA2979024C (enExample)
CL (1) CL2017002354A1 (enExample)
CO (1) CO2017009353A2 (enExample)
CR (1) CR20170468A (enExample)
DK (1) DK3271357T3 (enExample)
DO (1) DOP2017000209A (enExample)
EA (1) EA035739B1 (enExample)
EC (1) ECSP17069696A (enExample)
ES (1) ES2774052T3 (enExample)
GB (1) GB201504565D0 (enExample)
GE (2) GEP20207095B (enExample)
HU (1) HUE047918T2 (enExample)
IL (1) IL254277B (enExample)
MX (1) MX2017011902A (enExample)
MY (1) MY194873A (enExample)
NZ (1) NZ735631A (enExample)
PE (1) PE20180656A1 (enExample)
PH (1) PH12017501699B1 (enExample)
PT (1) PT3271357T (enExample)
SG (1) SG11201707280VA (enExample)
TN (1) TN2017000384A1 (enExample)
UA (1) UA123668C2 (enExample)
WO (1) WO2016148306A1 (enExample)
ZA (1) ZA201706612B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383747B (es) 2016-02-24 2025-03-14 Pfizer Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de quinasas janus (jak)
WO2019034973A1 (en) 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
DK3808747T3 (da) * 2018-09-13 2025-02-03 Kissei Pharmaceutical Imidazopyridinon-forbindelse
AU2020368368B2 (en) * 2019-10-14 2026-03-19 The Regents Of The University Of California Broad spectrum anti-cancer compounds
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
AR121626A1 (es) 2020-03-20 2022-06-22 Akebia Therapeutics Inc Compuestos inhibidores de phd, composiciones y métodos de uso
CN115413277B (zh) * 2020-04-20 2023-08-01 深圳市塔吉瑞生物医药有限公司 吡嗪取代的烟酰胺的固体形式及其制备和用途
JP7654071B2 (ja) * 2020-10-20 2025-03-31 アムジエン・インコーポレーテツド 複素環スピロ化合物及び使用方法
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
WO2023072240A1 (en) 2021-10-28 2023-05-04 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
JP2025500892A (ja) * 2021-12-17 2025-01-15 アケビア セラピューティクス インコーポレイテッド 選択的phd1阻害剤化合物、組成物、及び使用方法
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
DK135184A (da) * 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
NZ523807A (en) 2000-06-30 2004-09-24 Wyeth Corp Substituted-triazolopyrimidines as anticancer agents
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
US8283465B2 (en) * 2009-07-17 2012-10-09 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
JP2011168582A (ja) 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
JPWO2014030716A1 (ja) 2012-08-23 2016-08-08 田辺三菱製薬株式会社 ピラゾロピリミジン化合物

Also Published As

Publication number Publication date
JP2018512408A (ja) 2018-05-17
NZ735631A (en) 2023-07-28
DOP2017000209A (es) 2017-10-15
KR102609431B1 (ko) 2023-12-04
EP3271357A1 (en) 2018-01-24
AU2016234209B2 (en) 2020-08-27
CL2017002354A1 (es) 2018-05-04
CR20170468A (es) 2018-04-27
HK1249512A1 (en) 2018-11-02
IL254277A0 (en) 2017-10-31
WO2016148306A1 (en) 2016-09-22
ECSP17069696A (es) 2018-02-28
SG11201707280VA (en) 2017-10-30
PE20180656A1 (es) 2018-04-17
EA035739B1 (ru) 2020-08-03
EP3271357B1 (en) 2019-11-27
IL254277B (en) 2020-10-29
EA201792057A1 (ru) 2018-04-30
DK3271357T3 (da) 2020-02-17
PT3271357T (pt) 2020-02-21
GEP20207095B (en) 2020-04-10
ZA201706612B (en) 2019-01-30
PH12017501699B1 (en) 2023-06-30
ES2774052T3 (es) 2020-07-16
CA2979024A1 (en) 2016-09-22
UA123668C2 (uk) 2021-05-12
KR20170129874A (ko) 2017-11-27
PH12017501699A1 (en) 2018-03-12
MY194873A (en) 2022-12-21
JP6726681B2 (ja) 2020-07-22
US20180072714A1 (en) 2018-03-15
MX2017011902A (es) 2017-12-15
CN107531698B (zh) 2024-08-13
GEAP201914608A (en) 2019-10-10
BR112017019653B1 (pt) 2023-10-03
CA2979024C (en) 2024-02-20
TN2017000384A1 (en) 2019-01-16
AU2016234209A1 (en) 2017-10-12
BR112017019653A2 (pt) 2018-05-15
CN107531698A (zh) 2018-01-02
GB201504565D0 (en) 2015-05-06
US10287286B2 (en) 2019-05-14
CO2017009353A2 (es) 2017-11-30

Similar Documents

Publication Publication Date Title
ZA201706612B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
IL256808A (en) Heteroaryl derivatives as parp inhibitors
IL246140A0 (en) History of bicyclic heterocyclics as bromodomain repressors
ZA201801032B (en) Bicyclic compounds as atx inhibitors
IL253691B (en) Bicyclic heterocyclics as fgfr inhibitors
IL253869B (en) Bicyclic heterocyclics as fgfr4 inhibitors
ZA201800480B (en) New bicyclic compounds as dual atx/ca inhibitors
IL255570A (en) Bicyclic compounds as atx inhibitors
SI3371190T1 (sl) Heterociklične spojine kot inhibitorji PI3K gama
SG11201706729SA (en) Derivatives of sobetirome
IL253588B (en) History of bicyclic quinazolinones
IL255511B (en) New bicyclic compounds as dual atx/ca inhibitors
EP3323809A4 (en) Bicyclic heterocyclic amide derivative
IL255357A0 (en) bicyclic compounds
SMT201900019T1 (it) Derivati di tetraidrochinolina come inibitori di bromodominio
EP3275874A4 (en) Fused heterocyclic compound
ZA201706038B (en) Bicyclic pyridine compound